文献速递头颈部肿瘤放疗

头颈癌放化疗期间中期18F-FDG PET/CT管理的系统综述

Interim 18F-FDG PET/CT During Chemoradiation Therapy in the Management of Head and Neck Cancer Patients: A Systematic Review.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-03-04

本文系统综述了头颈癌患者放化疗期间中期FDG PET/CT(FDGint)的应用价值。多数研究证实FDGint可早期预测放化疗反应,但少数研究指出其预测价值不及放化疗结束后2至4个月的FDG PET/CT。最佳评估时机尚存争议,2周似乎最有利。

要点

  • 多数研究支持FDGint可早期预测头颈癌放化疗反应。
  • 少数研究认为FDGint预测价值低于放化疗后2至4个月的FDG PET/CT。
  • 放疗期间评估肿瘤反应的最佳时机仍有争议,2周似乎最有利。

核心结论

  • 多数研究证实FDGint在预测放化疗反应方面具有价值,但少数研究强调其预测价值不及放化疗结束后2至4个月采集的FDG PET/CT。
  • 放疗期间评估肿瘤反应的最佳时机仍是争议话题,2周似乎最有利,且仍提供调整治疗策略的机会。

研究设计与样本

  • 系统综述,评估放化疗期间采集的FDG PET(FDGint)在头颈癌管理中的应用。

主要发现

  • 多数研究证实FDGint可预测放化疗反应。
  • 少数研究指出FDGint预测价值不及放化疗结束后2至4个月采集的FDG PET/CT。
  • 放化疗结束后2至4个月的FDG PET/CT与局部和区域控制及生存良好相关。

临床怎么用

  • FDGint可用于早期识别肿瘤反应,必要时修改治疗计划或建立替代策略以提高治疗比。
  • 2周可能是评估肿瘤反应最有利的时机,但仍需根据肿瘤部位和放化疗方案在更同质、更大样本的系列中进一步分析。

局限性

  • 需在更同质、样本量更大且按肿瘤部位和放化疗方案分组的系列中进一步分析。
  • 放疗期间评估肿瘤反应的最佳时机尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Positron emission tomography (PET) is an imaging modality widely applied in oncology for tumor staging, volume delineation in radiation therapy planning, and therapy response assessment. F-18 fluorodeoxyglucose (FDG) PET combined with computed tomography plays a significant role in the management of locally advanced head and neck cancer patients in the pretreatment setting to predict outcome and prognosis and after chemoradiation therapy (CRT) to assess tumor response. This review aims to evaluate the use of FDG PET acquired during CRT, ad interim FDG (FDGint), to identify tumor response at an early stage, modify the treatment plan if necessary, or set up alternative strategies to enhance the therapeutic ratio. Most of the studies confirmed the value of FDGint in predicting the response to CRT, whereas a few highlighted the poor predictive value of FDGint compared with FDG acquired 2 to 4 months after the end of CRT, which was well correlated with local and regional control and survival. Such findings deserve to be further analyzed in more homogeneous series with greater patient numbers according to the tumor site and CRT schedules. The best time to assess tumor response during radiation therapy remains a matter of debate, although 2 weeks seems most favorable, still providing the opportunity to adapt the treatment strategy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Garibaldi C, Ronchi S, Cremonesi M, et al. Interim 18F-FDG PET/CT During Chemoradiation Therapy in the Management of Head and Neck Cancer Patients: A Systematic Review. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581396. doi:10.1016/j.ijrobp.2017.02.217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。